Project Grant R01DA059176
Award Date
8/15/23
Completion Date
7/30/26
Dollars Obligated
$3.1M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...
This Project Grant award of $3,011,183 from the National Institute on Drug Abuse (NIDA), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), supports research to investigate the effects of maternal opioid use disorder (OUD) on the placenta-brain axis and associated neurocognitive outcomes in offspring. The University of Kentucky Research Foundation, the prime awardee, will utilize a systems biology approach to integrate phenotypic, functional, and genomic data from the...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...
This $2,267,819 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Abuse and Addiction Research Programs) will fund research by the University of Washington to characterize extracellular vesicle (EV) profiles in healthy pregnancies and those complicated by opioid use disorder. The goal is to identify biomarkers in placental EVs and fetal brain/central nervous system EVs that could predict an infant's risk of developing neonatal opioid withdrawal syndrome (NOWS) and...
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400 pregnancies...
The National Institute on Drug Abuse (NIDA) awarded a Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) totaling $1,499,606.00 to the Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, with a project period from September 30, 2024 to July 31, 2029. The goal of this project is to characterize health outcomes from birth to 5 years of age in children born to individuals with opioid use disorder, identify disparities across populations,...
This federal Project Grant award, totaling $182,249, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will fund a study titled "Implementation of a Digitally Enhanced Intervention to Retain Pregnant and Postpartum People with Opioid Use Disorder in Buprenorphine Treatment" at the Medical University of South Carolina. The overall objective is to evaluate the feasibility and implementation of the...
This National Institute on Drug Abuse (NIDA) Project Grant award under CFDA 93.279 (Drug Use and Addiction Research Programs) provides $390,635 to the University of Pittsburgh to develop a novel intervention that addresses prenatal depressive symptoms to encourage tobacco and cannabis cessation among marginalized pregnant and postpartum people. The key products and services to be delivered through this grant include: 1) Conducting formative research on the experiences of marginalized pregnant...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...